{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:09:55Z","timestamp":1778584195602,"version":"3.51.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To investigate the prognostic value of RAS mutation status and subtypes in colorectal lung metastases (CRLM) patients undergoing image-guided thermal ablation (IGTA), and to evaluate survival outcomes under different systemic therapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In this multicenter retrospective\u2013prospective cohort study, 387 patients with CRLM who received percutaneous IGTA between March 2014 and December 2022 were included. Patients were stratified by RAS genotype (KRAS\/NRAS wild-type vs mutant). Survival outcomes including local tumor progression-free survival (LTPFS), progression-free survival (PFS), and overall survival (OS) were analyzed using Cox regression. Subgroup analyses were conducted based on chemotherapy regimens and targeted agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The 3-year LTP rate was significantly higher in KRAS-mutant patients (25.0%) than wild-type (15.0%). KRAS mutation, lesion diameter \u226520 mm, and elevated CEA were independent risk factors for LTP. Median PFS was 16.0\u00a0months; KRAS mutations predicted inferior PFS (13.3% vs 32.8% at 3\u00a0years). Median OS was significantly reduced in both KRAS (17.9 vs 56.8\u00a0months) and NRAS-mutant patients (22.1 vs 53.8\u00a0months). Among KRAS-mutant patients, FOLFOX plus bevacizumab yielded better OS than cetuximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RAS mutations are independent predictors of poor local control and survival after IGTA in CRLM. Evaluate interactions between RAS genotype and commonly used targeted agents in the peri-ablative setting. These integrated, real-world insights support the development of genotype-guided ablation planning and peri-ablative systemic therapy strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004089","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:03:01Z","timestamp":1771869781000},"page":"4230-4241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact"],"prefix":"10.1097","volume":"112","author":[{"given":"Hongjie","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China"},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging,Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China"},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging,Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Intervention, The First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Intervention, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Intervention, Ganzhou People\u2019s Hospital Hospital, Ganzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangping","family":"Cun","sequence":"additional","affiliation":[{"name":"Department of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences, Xiangyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuancheng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First People\u2019s Hospital of Yunnan Province, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Quzhou Hospital Affiliated to Wenzhou Medical University, Quzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahua","family":"Zou","sequence":"additional","affiliation":[{"name":"Cancer center, Huanggang Central Hospital, Huanggang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangwen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, China"},{"name":"Hubei Provincial Key Laboratory of Molecular Imaging,Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"R1-20260512","doi-asserted-by":"crossref","first-page":"1030\u201339","DOI":"10.1016\/j.athoracsur.2008.12.061","article-title":"Radiofrequency ablation for the treatment of pulmonary metastases","volume":"87","author":"Pennathur","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"686\u201395","DOI":"10.1148\/radiol.2020191272","article-title":"Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: a prospective multicenter study","volume":"294","author":"Hasegawa","year":"2020","journal-title":"Radiology"},{"key":"R3-20260512","doi-asserted-by":"crossref","first-page":"1189\u2013204","DOI":"10.1007\/s00270-018-1959-3","article-title":"Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis","volume":"41","author":"Meijerink","year":"2018","journal-title":"Cardiovasc Interv Radiol"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/jcm10102131","article-title":"Limited liver or lung colorectal cancer metastases. Systemic treatment, surgery, ablation or SBRT","volume":"10","author":"Molla","year":"2021","journal-title":"JCM"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"1018\u201325","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"720\u201328","DOI":"10.1038\/bjc.2014.499","article-title":"KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer","volume":"112","author":"Renaud","year":"2015","journal-title":"Br J Cancer"},{"key":"R7-20260512","first-page":"6252\u201361","article-title":"Genetic clustering of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy patients of colorectal origin: KRAS and not TP53 cluster alterations are associated with poor outcomes","volume":"31","author":"Yu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R8-20260512","doi-asserted-by":"crossref","first-page":"111717","DOI":"10.1016\/j.biopha.2021.111717","article-title":"The current understanding on the impact of KRAS on colorectal cancer","volume":"140","author":"Meng","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"4668\u201380","DOI":"10.1158\/0008-5472.CAN-19-4028","article-title":"ERK1\/2 signaling induces upregulation of ANGPT2 and CXCR4 to mediate liver metastasis in colon cancer","volume":"80","author":"Urosevic","year":"2020","journal-title":"Cancer Res"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/mmr.2024.13389","article-title":"KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF-\u03b2 mediated epithelial-mesenchymal transition","volume":"31","author":"Guo","year":"2025","journal-title":"Mol Med Rep"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"e2303740120","DOI":"10.1073\/pnas.2303740120","article-title":"KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas","volume":"120","author":"Hosaka","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1097\/MD.0000000000000580","article-title":"Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model","volume":"94","author":"Pillai","year":"2015","journal-title":"Medicine"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"15617","DOI":"10.1038\/ncomms15617","article-title":"Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance","volume":"8","author":"Ali","year":"2017","journal-title":"Nat Commun"},{"key":"R14-20260512","doi-asserted-by":"crossref","first-page":"2727\u201334","DOI":"10.1007\/s00330-017-5273-2","article-title":"Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival","volume":"28","author":"Calandri","year":"2018","journal-title":"Eur Radiol"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"4109\u201320","DOI":"10.2147\/IJGM.S428580","article-title":"KRAS\/NRAS mutations associated with distant metastasis and BRAF\/PIK3CA mutations associated with poor tumor differentiation in colorectal cancer","volume":"16","author":"Zeng","year":"2023","journal-title":"Int J Gen Med"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1038\/s41598-018-24306-1","article-title":"Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients","volume":"8","author":"Guo","year":"2018","journal-title":"Sci Rep"},{"key":"R17-20260512","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of artificial intelligence","author":"Agha","year":"2025","journal-title":"PJS"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"1386\u2013422","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"58\u201364","DOI":"10.1016\/j.semcdb.2016.08.034","article-title":"Gene heterogeneity in metastasis of colorectal cancer to the lung","volume":"64","author":"Hou","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"1269\u201380","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov"},{"key":"R21-20260512","first-page":"132\u201362","article-title":"\u201cundruggable KRAS\u201d: druggable after all","volume":"39","author":"Cox","year":"2025","journal-title":"Genes Dev"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"2081\u201389","DOI":"10.1038\/bjc.2014.100","article-title":"Activation of the PI3K\/AKT pathway correlates with prognosis in stage II colon cancer","volume":"110","author":"Malinowsky","year":"2014","journal-title":"Br J Cancer"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"1254\u201361","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"Jco"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"548\u201351","DOI":"10.1038\/nature12796","article-title":"K-ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"604\u201308","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"S1391","DOI":"10.1016\/j.annonc.2022.08.020","article-title":"LBA24 KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"33","author":"Klempner","year":"2022","journal-title":"Ann Oncol"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"727\u201336","DOI":"10.1158\/2159-8290.CD-23-1138","article-title":"Sotorasib is a pan-RASG12C inhibitor capable of driving clinical response in NRAS G12C cancers","volume":"14","author":"Rubinson","year":"2024","journal-title":"Cancer Discov"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"994\u20131017","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"2171\u201382","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS G12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/mco.2025.2873","article-title":"Targeting KRAS in colorectal cancer (review)","volume":"23","author":"Zhang","year":"2025","journal-title":"Mol Clin Oncol"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"E274","DOI":"10.1016\/S1470-2045(19)30172-X","article-title":"Explaining the unexplainable: discrepancies in results from the CALGB\/SWOG 80405 and FIRE-3 studies","volume":"20","author":"Aderka","year":"2019","journal-title":"Lancet Oncol"},{"key":"R33-20260512","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.annonc.2023.04.221","article-title":"P-165 first-line treatment with CET\/PAN vs. BEV in elderly patients with RAS WT mCRC: a multicenter real-world observational study by the japanese society for cancer of the colon and rectum","volume":"34","author":"Yamamoto","year":"2023","journal-title":"Ann Oncol"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-019-0702-0","article-title":"Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"70\u201383","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"109","author":"Modest","year":"2019","journal-title":"Eur J Cancer"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"1670\u201376","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: the gruppo oncologico nord ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"1609\u201318","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/cancers14030816","article-title":"Implications of RAS mutations on oncological outcomes of surgical resection and thermal ablation techniques in the treatment of colorectal liver metastases","volume":"14","author":"Rhaiem","year":"2022","journal-title":"Cancers"},{"key":"R39-20260512","doi-asserted-by":"crossref","first-page":"2619\u201326","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"R40-20260512","doi-asserted-by":"crossref","first-page":"2432988","DOI":"10.1080\/02656736.2024.2432988","article-title":"Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases","volume":"42","author":"Kong","year":"2025","journal-title":"Int J Hyperthermia"},{"key":"R41-20260512","first-page":"E369","article-title":"Mutation and methylation analysis of circulating tumor DNA can be used for follow-up of metastatic colorectal cancer patients","volume":"17","author":"Boeckx","year":"2018","journal-title":"Clin Colorectal Canc"},{"key":"R42-20260512","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:17:53Z","timestamp":1778581073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004089","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"2025-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}